Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 151

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 151
---
 in the earliest possible stage so
the individuals can continue living normal lives and maintain their independence.

In the early stage of Alzheimer’s,
a person may function independently. He or she may still drive, work, and participate in social activities. Despite this, the person may
feel as if he or she is having memory lapses, such as forgetting familiar words or the location of everyday objects.

Symptoms may not be widely
apparent at this stage, but family and close friends may take notice and a doctor would be able to identify symptoms using certain diagnostic
tools. Common difficulties include finding the right word or name, remembering names when meeting new people, and performing tasks in
social or work settings. People may also forget material they just read, lose or misplace valuable objects, and experience increased trouble
with planning or organizing.

This is the Alzheimer’s
disease patient category that we will include in our grant application for a proposed Phase II clinical trial with the final objective
of showing that JOTROL™ has the potential of slowing and/or possibly stopping the progression of this disease. The effect
of JOTROL™ treatment, in the Phase II trial, will primarily be measured through several biomarkers.

| 85 |

Economic burden of Alzheimer’s disease on society in USA is generating a very large opportunity

According to Alzheimer’s
Association’s 2020 annual report Alzheimer’s disease has impacted 5.7 million Americans and that it costs the US $277 billion
each year, excluding the cost of “unpaid time and effort of the people, mostly women, who are caring for spouses, parents, siblings,
and friends with dementia.” The Association explained, “In 2017, 16 million Americans provided an estimated 18.4 billion hours
of unpaid care in the form of physical, emotional and financial support - a contribution to the nation valued at $232.1 billion.”
Any product that delays the onset of severe Alzheimer’s disease should represent significant savings to society.

JNS108 Phase II Clinical Trial for MCI/early Alzheimer’s Disease

The proposed Phase II trial
is built on utilizing published information from the earlier Turner et al Phase II trial, completed in 2015 with 119 patients with early
Alzheimer’s disease who were treated with 4 different doses of resveratrol. The study was conducted by Professor Raymond Turner,
MD, Ph.D. at Georgetown University, a member of our Scientific Advisory Board, as the Principal Investigator. Dr. Turner is the Principal
Invest